Document is current
Any future updates will be listed below
-
Authors
Pichet Binette, Alexa https://orcid.org/0000-0001-5218-3337
Gaiteri, Chris
Wennström, Malin
Kumar, Atul
Hristovska, Ines
Spotorno, Nicola
Salvadó, Gemma https://orcid.org/0000-0002-5210-9230
Strandberg, Olof
Mathys, Hansruedi https://orcid.org/0000-0003-0186-2115
Tsai, Li-Huei https://orcid.org/0000-0003-1262-0592
Palmqvist, Sebastian https://orcid.org/0000-0002-9267-1930
Mattsson-Carlgren, Niklas
Janelidze, Shorena
Stomrud, Erik
Vogel, Jacob W.
Hansson, Oskar https://orcid.org/0000-0001-8467-7286
-
Funding
Funding for this research was provided by:
Vetenskapsrådet (2022-00775)
BrightFocus Foundation (A2021013F)
Fonds de Recherche du Québec - Santé (298314)
- License Information
-
More Information
Article History
Received: 26 August 2023
Accepted: 23 July 2024
First Online: 26 August 2024
Competing interests
: O.H. has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Eli Lilly, Fujirebio, Genentech, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. S.P. has acquired research support (for the institution) from ki elements/ADDF. In the past 2 years, he has received consultancy/speaker fees from Bioartic, Biogen, Lilly and Roche. The remaining authors declare no competing interests.
